PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.69%
Negative revenue growth while Medical - Pharmaceuticals median is 0.84%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-7.03%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.48%. Seth Klarman would suspect poor product pricing or inefficient production.
-15.27%
Negative EBIT growth while Medical - Pharmaceuticals median is 3.10%. Seth Klarman would check if external or internal factors caused the decline.
-30.94%
Negative operating income growth while Medical - Pharmaceuticals median is 4.97%. Seth Klarman would check if structural or cyclical issues are at play.
-15.78%
Negative net income growth while Medical - Pharmaceuticals median is 6.22%. Seth Klarman would investigate factors dragging net income down.
-15.82%
Negative EPS growth while Medical - Pharmaceuticals median is 3.17%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-15.82%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 3.17%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
-50.98%
Negative OCF growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-113.96%
Negative FCF growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
34.87%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 8.48%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
34.87%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 6.24%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
34.87%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 6.17%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.18%
Net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would confirm that management’s capital allocation strategy drives the outperformance.
78.18%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 40.64%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
78.18%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 23.35%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
46.81%
Equity/share CAGR of 46.81% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
46.81%
5Y equity/share CAGR of 46.81% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
46.81%
3Y equity/share CAGR of 46.81% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.76%
Inventory growth of 5.76% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
1.70%
Asset growth of 1.70% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.85%
BV/share growth of 4.85% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-12.38%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.